Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Phase 1a
Aged 18 years or older
Histologically or cytologically confirmed solid tumor or hematologic malignancy
Life expectancy of 12 weeks or longer
Must have received ≥ 1 prior treatment regimen
Must not be a candidate for potentially curative or standard of care approved therapy
Phase 1b
Aged 18 years or older
Cohort A: Histologically or cytologically confirmed pancreatic adenocarcinoma, triple-negative breast cancer, urothelial cancer with at least 1 measurable or evaluable target lesion
Cohorts B, C, D, E and G: Histologically confirmed multiple myeloma and measureable/evaluable disease
Cohort F: Confirmed acute myeloid leukemia or myelodysplastic syndrome
Cohort H: Individuals diagnosed with lymphoma
Prior therapy:
* Cohort A: No more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy)
* Cohorts B, C, D, E and G: Must have relapsed from or have been refractory to ≥ 2 prior treatment regimens
* Cohort F: May have received any number of prior treatment regimens or be treatment-naïve
* Cohort H: Must have relapsed from or have been refractory to available treatments
Phase 2
Aged 18 years or older
Cohorts I and J: Confirmed acute myeloid leukemia or high risk myelodysplastic syndrome
Prior therapy:
* Cohorts I and J: Must have failed prior therapy with a hypomethylating agent (HMA)
You may not be if
Prior receipt of a JAK1 inhibitor (Phase 1a only)
Known active central nervous system metastases and/or carcinomatous meningitis
Eastern Cooperative Oncology Group (ECOG) performance status \> 2
Any known contraindications to the use of gemcitabine, nab-paclitaxel, dexamethasone, carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide or PI3Kδ inhibitor (Phase 1b and Phase 2 only, as appropriate to treatment cohort)
Known human immunodeficiency virus infection, or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation
Clareo Health | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
